Cargando…

Comparing cellular bone matrices for posterolateral spinal fusion in a rat model

INTRODUCTION: Cellular bone matrices (CBM) are allograft products that provide three components essential to new bone formation: an osteoconductive scaffold, extracellular growth factors for cell proliferation and differentiation, and viable cells with osteogenic potential. This is an emerging techn...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Cliff, Zhang, Nianli, Waldorff, Erik I., Punsalan, Paolo, Wang, David, Semler, Eric, Ryaby, James T., Yoo, Jung, Johnstone, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323463/
https://www.ncbi.nlm.nih.gov/pubmed/32613160
http://dx.doi.org/10.1002/jsp2.1084
_version_ 1783551775623610368
author Lin, Cliff
Zhang, Nianli
Waldorff, Erik I.
Punsalan, Paolo
Wang, David
Semler, Eric
Ryaby, James T.
Yoo, Jung
Johnstone, Brian
author_facet Lin, Cliff
Zhang, Nianli
Waldorff, Erik I.
Punsalan, Paolo
Wang, David
Semler, Eric
Ryaby, James T.
Yoo, Jung
Johnstone, Brian
author_sort Lin, Cliff
collection PubMed
description INTRODUCTION: Cellular bone matrices (CBM) are allograft products that provide three components essential to new bone formation: an osteoconductive scaffold, extracellular growth factors for cell proliferation and differentiation, and viable cells with osteogenic potential. This is an emerging technology being applied to augment spinal fusion procedures as an alternative to autografts. METHODS: We aim to compare the ability of six commercially‐available human CBMs (Trinity ELITE®, ViviGen®, Cellentra®, Osteocel® Pro, Bio4® and Map3®) to form a stable spinal fusion using an athymic rat model of posterolateral fusion. Iliac crest bone from syngeneic rats was used as a control to approximate the human gold standard. The allografts were implanted at L4‐5 according to vendor specifications in male athymic rats, with 15 rats in each group. MicroCT scans were performed at 48 hours and 6 weeks post‐implantation. The rats were euthanized 6 weeks after surgery and the lumbar spines were harvested for X‐ray, manual palpation and histology analysis by blinded reviewers. RESULTS: By manual palpation, five of 15 rats of the syngeneic bone group were fused at 6 weeks. While Trinity ELITE had eight of 15 and Cellentra 11 of 15 rats with stable fusion, only 2 of 15 of ViviGen‐implanted spines were fused and zero of 15 of the Osteocel Pro, Bio4 and Map3 produced stable fusion. MicroCT analysis indicated that total bone volume increased from day 0 to week 6 for all groups except syngeneic bone group. Trinity ELITE (65%) and Cellentra (73%) had significantly greater bone volume increases over all other implants, which was consistent with the histological analysis. CONCLUSION: Trinity ELITE and Cellentra were significantly better than other implants at forming new bone and achieving spinal fusion in this rat model at week 6. These results suggest that there may be large differences in the ability of different CBMs to elicit a successful fusion in the posterolateral spine.
format Online
Article
Text
id pubmed-7323463
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-73234632020-06-30 Comparing cellular bone matrices for posterolateral spinal fusion in a rat model Lin, Cliff Zhang, Nianli Waldorff, Erik I. Punsalan, Paolo Wang, David Semler, Eric Ryaby, James T. Yoo, Jung Johnstone, Brian JOR Spine Methods Papers INTRODUCTION: Cellular bone matrices (CBM) are allograft products that provide three components essential to new bone formation: an osteoconductive scaffold, extracellular growth factors for cell proliferation and differentiation, and viable cells with osteogenic potential. This is an emerging technology being applied to augment spinal fusion procedures as an alternative to autografts. METHODS: We aim to compare the ability of six commercially‐available human CBMs (Trinity ELITE®, ViviGen®, Cellentra®, Osteocel® Pro, Bio4® and Map3®) to form a stable spinal fusion using an athymic rat model of posterolateral fusion. Iliac crest bone from syngeneic rats was used as a control to approximate the human gold standard. The allografts were implanted at L4‐5 according to vendor specifications in male athymic rats, with 15 rats in each group. MicroCT scans were performed at 48 hours and 6 weeks post‐implantation. The rats were euthanized 6 weeks after surgery and the lumbar spines were harvested for X‐ray, manual palpation and histology analysis by blinded reviewers. RESULTS: By manual palpation, five of 15 rats of the syngeneic bone group were fused at 6 weeks. While Trinity ELITE had eight of 15 and Cellentra 11 of 15 rats with stable fusion, only 2 of 15 of ViviGen‐implanted spines were fused and zero of 15 of the Osteocel Pro, Bio4 and Map3 produced stable fusion. MicroCT analysis indicated that total bone volume increased from day 0 to week 6 for all groups except syngeneic bone group. Trinity ELITE (65%) and Cellentra (73%) had significantly greater bone volume increases over all other implants, which was consistent with the histological analysis. CONCLUSION: Trinity ELITE and Cellentra were significantly better than other implants at forming new bone and achieving spinal fusion in this rat model at week 6. These results suggest that there may be large differences in the ability of different CBMs to elicit a successful fusion in the posterolateral spine. John Wiley & Sons, Inc. 2020-03-15 /pmc/articles/PMC7323463/ /pubmed/32613160 http://dx.doi.org/10.1002/jsp2.1084 Text en © 2020 The Authors. JOR Spine published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Methods Papers
Lin, Cliff
Zhang, Nianli
Waldorff, Erik I.
Punsalan, Paolo
Wang, David
Semler, Eric
Ryaby, James T.
Yoo, Jung
Johnstone, Brian
Comparing cellular bone matrices for posterolateral spinal fusion in a rat model
title Comparing cellular bone matrices for posterolateral spinal fusion in a rat model
title_full Comparing cellular bone matrices for posterolateral spinal fusion in a rat model
title_fullStr Comparing cellular bone matrices for posterolateral spinal fusion in a rat model
title_full_unstemmed Comparing cellular bone matrices for posterolateral spinal fusion in a rat model
title_short Comparing cellular bone matrices for posterolateral spinal fusion in a rat model
title_sort comparing cellular bone matrices for posterolateral spinal fusion in a rat model
topic Methods Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323463/
https://www.ncbi.nlm.nih.gov/pubmed/32613160
http://dx.doi.org/10.1002/jsp2.1084
work_keys_str_mv AT lincliff comparingcellularbonematricesforposterolateralspinalfusioninaratmodel
AT zhangnianli comparingcellularbonematricesforposterolateralspinalfusioninaratmodel
AT waldorfferiki comparingcellularbonematricesforposterolateralspinalfusioninaratmodel
AT punsalanpaolo comparingcellularbonematricesforposterolateralspinalfusioninaratmodel
AT wangdavid comparingcellularbonematricesforposterolateralspinalfusioninaratmodel
AT semlereric comparingcellularbonematricesforposterolateralspinalfusioninaratmodel
AT ryabyjamest comparingcellularbonematricesforposterolateralspinalfusioninaratmodel
AT yoojung comparingcellularbonematricesforposterolateralspinalfusioninaratmodel
AT johnstonebrian comparingcellularbonematricesforposterolateralspinalfusioninaratmodel